Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Marrone Bio (MBII), Elephant Vert Ink Distribution Deal

Published 09/25/2017, 08:45 AM
Updated 07/09/2023, 06:31 AM

Marrone Bio Innovations, Inc. (NASDAQ:MBII) and Elephant Vert entered into a distribution deal under which the latter will develop and market two of Marrone Bio’s products namely, the biofungicide Reysana and bionematicide Majestene, in Tunisia, Morocco and Algeria.

Bionematicide Majestene protects crops from yield-robbing nematodes and is currently under the process of registration. Biofungicide Reysana is used by growers of peppers, tomatoes, cucurbits and grapes. It contains same ingredients as Marrone Bio’s Regalia Maxx Biofungicide, which is presently marketed and sold in more than 10 countries.

The two pioneering companies in the biological crop protection market have the knowledge and products to bring sustainable solutions, which can improve both quality and yield to farmers in North Africa.

Elephant Vert is a Swiss group that develops and markets biofertilizers, organic amendments, biostimulants and natural biopesticides produced in four production units. According to Elephant Vert, integration of biopesticides into crop protection programs is increasingly important for exporters of vegetables in the region and also benefits all production. The deal opens up potential development opportunities to offer growers in North Africa with a vast range of innovative, efficient and natural solutions.

Marrone Bio has underperformed the industry it belongs to over a year. The company’s shares have lost around 33.8% over this period compared against the industry’s gain of 29%.

Marrone Biorecorded a net loss of $7.4 million or 25 cents per share in second-quarter 2017, compared with a loss of $6.8 million or 28 cents per share a year ago. Loss per share for the quarter was wider than the Zacks Consensus Estimate of a loss of 21 cents.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The company, in second quarter earnings call, announced that it is seeing above industry average growth for its products driven by its portfolio approach to product development and marketing that focuses on addressing unmet market needs and promotes substantial growth opportunities. It is gaining from efforts to grow revenues from existing as well as new products and strategic partnerships in the United States and overseas markets. The company expects its ongoing manufacturing improvement initiatives in research and development to contribute to a meaningful improvement in margins over the long term.

Zacks Rank & Stocks to Consider

Marrone Bio currently carries a Zacks Rank #3 (Hold).

Some better-ranked companies in the basic materials space include Sociedad Quimica y Minera S.A. (NYSE:SQM) , Koppers Holdings Inc. (NYSE:KOP) and Kronos Worldwide Inc. (NYSE:KRO) . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.

Sociedad Quimica has an expected long-term earnings growth rate of 32.5%.

Koppers has an expected long-term earnings growth rate of 18%.

Kronos has an expected long-term earnings growth rate of 5%.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

See the pot trades we're targeting>>



Kronos Worldwide Inc (KRO): Free Stock Analysis Report

Koppers Holdings Inc. (KOP): Free Stock Analysis Report

Marrone Bio Innovations, Inc. (MBII): Free Stock Analysis Report

Sociedad Quimica y Minera S.A. (SQM): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.